Journal of General Internal Medicine

, Volume 10, Issue 5, pp 273–282 | Cite as

Hepatitis C

Diagnosis and treatment
  • Ilias Scotiniotis
  • Clifford A. Brass
  • Peter F. Malet
Clinical Reviews

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Prince AM, Brotman B, Grady GF, et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis B virus. Lancet. 1974;2:241–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975;292:767–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Kuo G, Choo QL, Alter HJ. et al. An assay of circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Alter M, Hadler S, Judson FN. et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C infection. JAMA. 1990;264:2231–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Jeffers LJ, Hasan F, De Medina M, et al. Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. Hepatology. 1992;15:187–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Weiland O, Schvarcz R. Hepatitis C: virology, epidemiology, clinical course, and treatment. Scand J Gastroenterol. 1992;27:337–42.PubMedGoogle Scholar
  8. 8.
    Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology. 1994;107:189–95.PubMedGoogle Scholar
  9. 9.
    Yoshiba M, Dehara K, Inoue K, Okamoto H, Mayumi M. Contribution of hepatitis C virus to non-A, non-B fulminant hepatitis in Japan. Hepatology. 1994;19:829–35.PubMedGoogle Scholar
  10. 10.
    Esteban JI, Genesca J, Alter HJ. Hepatitis C: molecular biology, pathogenesis. epidemiology, clinical features, and prevention. In: Boyer JL, Ockner RK (eds). Progress in Liver Diseases. Philadelphia: W. B. Saunders, 1992:253–82.Google Scholar
  11. 11.
    Alter MJ, Margolis HS, Krawczynski K, et al. Natural history of community-acquired hepatitis C in the United States. N Engl J Med. 1992;327:1899–905.PubMedCrossRefGoogle Scholar
  12. 12.
    Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease [letter]. Lancet. 1993;341:464–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Navas S, Castillo I, Carreno V. Detection of plus and minus HCV RNA in normal liver of anti-HCV-positive patients [letter]. Lancet. 1993;341:904–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Naito M, Hayashi N, Hagiwara H, et al. Serum hepatitis C virus RNA quantity and histologic features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology. 1994;19:871–5.PubMedGoogle Scholar
  15. 15.
    Sanchez-Tapias JM, Barrera J, Costa J, et al. Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med. 1990;112:921–4.PubMedGoogle Scholar
  16. 16.
    Hopf U, Möller B, Küther D, et al. Long-term follow-up of post-transfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol. 1990;10:69–76.PubMedCrossRefGoogle Scholar
  17. 17.
    Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut. 1993;34(suppl 2):S13-S16.PubMedGoogle Scholar
  18. 18.
    Kim-Deabald J, Bauermeister D, Bredfeldt J, Fenster LF, Rosoff L. The histologic progression of mild chronic hepatitis C [abstract], Gastroenterology. 1993:104;A927.Google Scholar
  19. 19.
    Czaja AJ. Chronic active hepatitis: the challenge for a new nomenclature. Ann Intern Med. 1993;119:510–7.PubMedGoogle Scholar
  20. 20.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–20.PubMedGoogle Scholar
  21. 21.
    DiBesceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 1992;14:969–74.Google Scholar
  22. 22.
    Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology. 1992;15:567–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Bach N, Thung SN, Schaffner F. The histologic features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15:572–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Resnick RH, Koff R. Hepatitis C-related hepatocellular carcinoma: prevalence and significance. Arch Intern Med. 1993;153:1672–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989;2:1006–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Nishioka K, Watanabe J, Furuta S, et al. A high prevalence of the antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer. 1991;67:429–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989;2:1004–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Alter HJ. Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective. Ann Intern Med. 1991;115:644–9.PubMedGoogle Scholar
  29. 29.
    Esteban JI, Esteban R, Viladomiu L, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet. 1989;2:294–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood. 1990;76:254–6.PubMedGoogle Scholar
  31. 31.
    Tor J, Llibre J, Carbonell M, et al. Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. Br Med J. 1990;301:1130–3.Google Scholar
  32. 32.
    Akahane Y, Kojima M, Sugai Y, et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med. 1994;120:748–52.PubMedGoogle Scholar
  33. 33.
    Thaler M, Park CK, Landers D, et al. Vertical transmission of hepatitis C virus. Lancet. 1991;338:17–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med. 1994;330:744–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Novati R, Thiers V, Monforte A, et al. Mother-to-child transmission of hepatitis C virus detected by nested polymerase chain reaction. J Infect Dis. 1992;165:720–3.PubMedGoogle Scholar
  36. 36.
    Klein RS, Freeman K, Taylor PE, Stevens CE. Occupational risk for hepatitis C virus infection among New York City dentists. Lancet. 1991;338:1539–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Houghton M, Weiner A, Han J, Kuo G, Choo QL. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology. 1991;14:381–8.PubMedGoogle Scholar
  38. 38.
    Takamizawa A, Mori C, Fuke I, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol. 1991;65:1105–13.PubMedGoogle Scholar
  39. 39.
    Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74:2391–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative El gene of isolates collected worldwide. Proc Natl Acad Sci. 1993;90:8234–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Sugitani M, Inchaupse G, Shindo M, Prince AM. Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet. 1992;339:1018–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in posttransfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med. 1991;325:1325–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to hepatitis C virus. Hepatology. 1992;15:350–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Van Der Poel CL, Cuypers HTM, Reesink HW, et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet. 1991;337:317–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Brechot C. Polymerase chain reaction: a new tool for the study of viral infections in hepatology. J Hepatol. 1990;11:124–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Weiner AJ, Kuo G, Bradley DW, et al. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet. 1990;335:1–3.PubMedCrossRefGoogle Scholar
  47. 47.
    Carson JA, Tedder RS, Briggs M, et al. Detection of hepatitis C viral sequences in blood donations by “nested” polymerase chain reaction and prediction of infectivity. Lancet. 1990;335:1419–22.CrossRefGoogle Scholar
  48. 48.
    Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest. 1990;86:1764–7.PubMedGoogle Scholar
  49. 49.
    Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology. 1993;18:16–20.PubMedGoogle Scholar
  50. 50.
    Cristiano K, DiBesceglie AM, Hoofnagle JH, Feinstone SM. Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: detection by the polymerase chain reaction using multiple primer sets. Hepatology. 1991;14:51–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Urdea MS, Horn T, Fultz TJ, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Res Symp Ser. no. 24. 1991;24:197–200.Google Scholar
  52. 52.
    Chazouilleres O, Kim M, Ferrell L, et al. Quantitative study of hepatitis C virus (HCV) in liver transplant (OLTx) recipients [abstract]. Hepatology. 1992;16:45A.Google Scholar
  53. 53.
    Ferenci P. Historical treatment of chronic hepatitis B and chronic hepatitis C. Gut. 1993;34(suppl 2):S69-S73.PubMedGoogle Scholar
  54. 54.
    Dianzani F. Biological basis for the clinical use of interferon. Gut. 1993;34(suppl 2):S74-S76.PubMedGoogle Scholar
  55. 55.
    Peters M. Mechanisms of action of interferons. Semin Liver Dis. 1989;9:235–9.PubMedGoogle Scholar
  56. 56.
    Saez-Roquela F, Porres JC, Moreno A, et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: randomized controlled trial. Hepatology. 1991;13:327–31.CrossRefGoogle Scholar
  57. 57.
    Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic hepatitis non-A, non-B with recombinant human interferon-alpha; a preliminary report. N Engl J Med. 1986;315:1575–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–10.PubMedCrossRefGoogle Scholar
  59. 59.
    Marcellin P, Boyer N, Giostra E, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991;13:393–7.PubMedGoogle Scholar
  60. 60.
    Douglas DD, Rakela J, Ju Lin H, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Dig Dis Sci. 1993;38:601–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Davis GL, Balart LA. Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med. 1989;321:1501–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol. 1991;13:192–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Dusheiko GM. The pathogenesis, diagnosis and management of viral hepatitis. Aliment Pharmacol Ther. 1994;8:229–53.PubMedCrossRefGoogle Scholar
  64. 64.
    Perillo RP. Antiviral agents in the treatment of chronic viral hepatitis. In: Boyer JL, Ockner RK (eds). Progress in Liver Diseases. Philadelphia: W. B. Saunders, 1992:283–309.Google Scholar
  65. 65.
    Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991;101:497–502.PubMedGoogle Scholar
  66. 66.
    Lin R, Zimmerman M, Roach E, Farrell G. Alpha-interferon 2b in the treatment of chronic active hepatitis C: interim report of the first multicenter Australian trial [abstract]. Hepatology. 1992;16:75A.Google Scholar
  67. 67.
    Lino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon α-2b. Dig Dis Sci. 1993;38:612–8.CrossRefGoogle Scholar
  68. 68.
    Alberti A, Chemello L, Diodati G, et al. Treatment of chronic hepatitis C with different regimens of interferon alpha-2 [abstract). Hepatology. 1992;16:75A.Google Scholar
  69. 69.
    Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis treated with different doses of interferon-β. Hepatology. 1993;18:1300–5.PubMedGoogle Scholar
  70. 70.
    Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-β for 60 weeks. Hepatology. 1994;19:280–5.PubMedGoogle Scholar
  71. 71.
    Bosch O, Tapia L, Quiroga JA, Carreno V. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C. J Hepatol. 1993;17:146–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Castillo I, Bartolome J, Navas S, Gonzalez S, Herrero M, Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology. 1994;19:1342–6.PubMedGoogle Scholar
  73. 73.
    Marriott E, Quiroga JA, Carreno V. Retreatment of chronic hepatitis C with interferon alpha. J Infect Dis. 1992;166:1200–1.PubMedGoogle Scholar
  74. 74.
    Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology. 1992;15:1013–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Magrin S, Craxi A, Fabiano C, et al. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. J Med Virol. 1992;38:200–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology. 1993;104:877–83.PubMedGoogle Scholar
  77. 77.
    Shindo M, Di Bisceglie AM, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991;115:700–4.PubMedGoogle Scholar
  78. 78.
    Schiff ER. Treatment algorithms for hepatitis B and C. Gut. 1993;34(suppl 2):S148-S149.PubMedGoogle Scholar
  79. 79.
    Yee HF, Wright TL. Serum ALT. Tarnished gold standard for interferon response in hepatitis C virus infection. Hepatology. 1994;19:1531–3.PubMedGoogle Scholar
  80. 80.
    Johnson Y, Lau N, Mizokami M, et al. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 1993;342:1208–9.CrossRefGoogle Scholar
  81. 81.
    Davis GL, Lindsay K, Albrecht J, et al. Predictors of response to recombinant alpha interferon in patients with chronic hepatitis C [abstract]. Hepatology. 1990;12:905A.Google Scholar
  82. 82.
    Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology. 1994;19:1088–94.PubMedGoogle Scholar
  83. 83.
    Pagliaro L, Craxí A, Cammaá C, et al. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology. 1994;19:820–8.PubMedGoogle Scholar
  84. 84.
    Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription—polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology. 1993;18:16–20.PubMedGoogle Scholar
  85. 85.
    Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis. 1989;9:273–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Lisker-Melamn M, Di Besceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992;102:2155–60.Google Scholar
  87. 87.
    Renault PF, Hoofnagle JH, Park Y. et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med. 1987;147:1577–80.PubMedCrossRefGoogle Scholar
  88. 88.
    Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-a for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis. 1992;165:723–6.PubMedGoogle Scholar
  89. 89.
    Casato M, Pucillo L, Lagana B, Taliani G, Goffredo F, Bonomo L. Cryoglobulinemia and hepatitis C virus. Lancet. 1991337:1047–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Ferri C, Zignego AL, Longombardo G, et al. Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. Infection. 1993;27:93–7.CrossRefGoogle Scholar
  91. 91.
    Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330:751–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Omata M, Yokosuka O, Takano S, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet. 1991;338:914–5.PubMedCrossRefGoogle Scholar
  93. 93.
    Rumi MG. Lampertico P, Soffredini R. et al. Serum HCV-RNA in patients with acute hepatitis C treated with recombinant interferon alfa [abstract]. Gastroenterology. 1993;104:981A.Google Scholar
  94. 94.
    Viladomiu L, Genesca J, Esteban Jl, et al. Interferon-a in acute posttransfusional hepatitis C: a randomized, controlled trial. Hepatology. 1992;15:767–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Mitchel LS, Jeffers LJ, Reddy KR, et al. Detection of hepatitis C virus antibody by first and second generation assays and polymerase chain reaction in patients with autoimmune chronic active hepatitis types I, II. and III. Am J Gastroenterol. 1993;88:1027–34.PubMedGoogle Scholar
  96. 96.
    Czaja AJ, Taswell HF, Rakela J, Schimek CM. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. Mayo Clin Proc. 1991;66:572–82.PubMedGoogle Scholar
  97. 97.
    Nishiguchi S, Kuroki T, Ueda T, et al. Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med. 1992;116:21–5.PubMedGoogle Scholar
  98. 98.
    Davis GL. Hepatitis C antibody in patients with chronic autoimmune hepatitis: pitfalls in diagnosis and implications for treatment. Mayo Clin Proc. 1991;66:647–50.PubMedGoogle Scholar
  99. 99.
    Black M. Alpha-interferon treatment of chronic hepatitis C; need for accurate diagnosis in selecting patients. Ann Intern Med. 1992;116:86–7.PubMedGoogle Scholar
  100. 100.
    Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alpha therapy for chronic hepatitis C. Gastroenterol. 1992;102:1406–8.Google Scholar
  101. 101.
    Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103:317–22.PubMedGoogle Scholar
  102. 102.
    Wright TL. Hepatitis C virus and organ transplantation. In: Boyer JL, Ockner RK (eds). Progress in Liver. Diseases. Philadelphia: W. B. Saunders, 1992:215–30.Google Scholar
  103. 103.
    Kiyosawa K. Sodeyama T, Tanaka E. et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med. 1991;115:367–9.PubMedGoogle Scholar
  104. 104.
    Di Bisceglie AM, Fried MW, Swain MG, et al. Randomized, double-blind, placebo-controlled trial of ribavirin therapy for chronic hepatitis C [abstract]. Hepatology. 1993;18:93A.Google Scholar
  105. 105.
    Lai MY, Yang PM, Kac JH, Wang JT, Lee HS, Chen DS. Combination therapy of α-interferon and ribavirin in patients with chronic hepatitis C: an interim report [abstract]. Hepatology. 1993;18:93A.Google Scholar
  106. 106.
    Civeira MP, Castilla A, Morte S, Serrano M, Prieto J. A pilot study of thymus extract in chronic non-A, non-B hepatitis. Aliment Pharmacol Ther. 1989;3:395–401.PubMedCrossRefGoogle Scholar
  107. 107.
    O’Brien CB, Brass CA, Long WB, Rubin RA, Kincaid MC, Henzel B. Ursodiol and interferon alfa-2b for the treatment of chronic hepatitis C [abstract]. Gastroenterology. 1993;104:966A.Google Scholar

Copyright information

© Society of General Internal Medicine 1995

Authors and Affiliations

  • Ilias Scotiniotis
  • Clifford A. Brass
  • Peter F. Malet
    • 1
  1. 1.Gastroenterology DivisionUniversity of PennsylvaniaPhiladelphia

Personalised recommendations